Study of SANGUINATE™ Versus Hydroxyurea in Sickle Cell Disease (SCD) Patients
Study of SANGUINATE™ Versus Hydroxyurea in Sickle Cell Disease (SCD) Patients
The purpose of this study is to compare the safety of SANGUINATE™ versus Hydroxyurea in
 patients suffering from Sickle Cell Disease.
Inclusion Criteria:

 -  Patients with Homozygous (HbSS) Sickle Cell Anemia;

 -  Hb levels: >6g/dL - <10g/dL;

 -  Age : >18 years old;

 -  Frequency of ER hospitalizations < 6x/yr for SCD pain events documented "medical
 history".

 Exclusion Criteria:

 -  Patients, who are on chronic transfusion program, defined as regular transfusions
 every 2-8 weeks;

 -  Allergic to Hydroxyurea;

 -  History of clinical significant disease, as determined by the Investigator;

 -  History of allergy or major allergic reaction considered to be clinically significant
 by the Investigator;

 -  Screening assessments considered to be abnormal by the Investigator;

 -  Patient has sever pulmonary hypertension (index >3 meters per sec);

 -  Donated blood within 60 days of screening or otherwise experienced blood loss of >250
 mL within the same period;

 -  Intending to begin new concomitant drug therapy or over-the-counter medication anytime
 from scree4nin to the time of administration of study drug;